John C. Byrd

6.2k total citations · 1 hit paper
81 papers, 3.7k citations indexed

About

John C. Byrd is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, John C. Byrd has authored 81 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Genetics, 32 papers in Hematology and 24 papers in Molecular Biology. Recurrent topics in John C. Byrd's work include Chronic Lymphocytic Leukemia Research (47 papers), Acute Myeloid Leukemia Research (21 papers) and Lymphoma Diagnosis and Treatment (19 papers). John C. Byrd is often cited by papers focused on Chronic Lymphocytic Leukemia Research (47 papers), Acute Myeloid Leukemia Research (21 papers) and Lymphoma Diagnosis and Treatment (19 papers). John C. Byrd collaborates with scholars based in United States, United Kingdom and Italy. John C. Byrd's co-authors include Kristie A. Blum, Gerard Lozanski, Guido Marcucci, Michael R. Grever, David Lucas, John C. Reed, Andrew P. Mone, Melanie E. Davis, Shinichi Kitada and Mark R. Parthun and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

John C. Byrd

75 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

2002 1.2k citations John C. Byrd Blood profile →

Peers

Countries citing papers authored by John C. Byrd

Since Specialization

Citations

This map shows the geographic impact of John C. Byrd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Byrd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Byrd more than expected).

Fields of papers citing papers by John C. Byrd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Byrd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Byrd. The network helps show where John C. Byrd may publish in the future.

Co-authorship network of co-authors of John C. Byrd

This figure shows the co-authorship network connecting the top 25 collaborators of John C. Byrd. A scholar is included among the top collaborators of John C. Byrd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Byrd. John C. Byrd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies 2025 ·Leukemia ·(unknown), Deedra Nicolet, (unknown), Daelynn R. Buelow, Shelley Orwick, Charles T. Gregory, (unknown), (unknown), Jonathan E. Kolitz, Bayard L. Powell, William Blum, Maria R. Baer, John C. Byrd, Wendy Stock, Geoffrey L. Uy, Krzysztof Mrózek, Ann‐Kathrin Eisfeld, Xiaolin Cheng, Sharyn D. Baker, James S. Blachly	1
2	Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1 2025 ·Nature ·Puneet Agarwal, (unknown), Kathleen Hueneman, (unknown), Niels Asger Jakobsen, (unknown), (unknown), Jennifer Yeung, Lyndsey Bolanos, Xueheng Zhao, Kenneth D.R. Setchell, David Haslam, Jessica Galloway-Peña, John C. Byrd, Paresh Vyas, Daniel T. Starczynowski	11
3	Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation 2024 ·Leukemia ·(unknown), (unknown), (unknown), (unknown), (unknown), Patrick Ruz, Adam S. Kittai, Kerry A. Rogers, Michael R. Grever, Seema A. Bhat, Tracy Wiczer, John C. Byrd, Jennifer A. Woyach, Daniel Addison	5
4	Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects 2024 ·Blood ·Anthony G. Mansour, Ying Huang, (unknown), Adam S. Kittai, John C. Byrd, Michael R. Grever, Cecelia Miller, Gerard Lozanski, Mollie E. Moran, Margaret S. Lucas, (unknown), (unknown), (unknown), Mark W. Reid, Kerry A. Rogers, Seema A. Bhat, (unknown)	0
5	B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy 2023 ·Clinical Cancer Research ·Jennifer A. Woyach, Paolo Ghia, John C. Byrd, Inhye E. Ahn, Carol Moreno, Susan O’Brien, Dan Jones, Leo W.K. Cheung, Elizabeth Chong, Kevin Kwei, James P. Dean, Danelle F. James, Adrian Wiestner	7
6	First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma 2023 ·Cancer Discovery ·Jennifer A. Woyach, Deborah M. Stephens, Ian W. Flinn, Seema A. Bhat, Ronald E. Savage, (unknown), Sudharshan Eathiraj, Sean D. Reiff, (unknown), (unknown), (unknown), (unknown), Brian Schwartz, Razi Ghori, Mohammed Z.H. Farooqui, John C. Byrd	29
7	Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization 2023 ·Blood Advances ·(unknown), (unknown), Adam S. Kittai, Seema A. Bhat, Michael R. Grever, Kerry A. Rogers, Weiqiang Zhao, Dan Jones, John C. Byrd, Matthew R. Avenarius, Nyla A. Heerema, Jennifer A. Woyach, Cecelia Miller	4
8	Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial 2023 ·Blood ·John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan‐Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony R. Mato, Stephan Stilgenbauer, (unknown), (unknown), Kara Higgins, (unknown), (unknown), Wojciech Jurczak, Jennifer A. Woyach	62
9	The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy 2023 ·Blood ·(unknown), (unknown), Sandip Vibhute, Tiffany Hughes, Susheela Tridandapani, Megan Johnstone, Thomas E. Goodwin, (unknown), Chad Bennett, Don Benson, John C. Byrd, Ola A. Elgamal, Erin Hertlein	0
10	Clonal hematopoiesis of indeterminate potential in the companion dog 2022 ·Leukemia ·(unknown), Hatice Gülçin Özer, (unknown), (unknown), Arletta Lozanski, (unknown), Shelley Orwick, Gerard Lozanski, Wenjuan Ma, William C. Kisseberth, John C. Byrd, Bonnie K. Harrington	3
11	HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia 2022 ·Blood Advances ·(unknown), Hatice Gülçin Özer, Pierluigi Gasparini, Giovanni Nigita, Rosario Distefano, (unknown), (unknown), (unknown), Juan Gallegos, Sachet A. Shukla, Vinay K. Puduvalli, Jennifer A. Woyach, Rosa Lapalombella, James S. Blachly, John C. Byrd, Deepa Sampath	7
12	649TiP A phase I/Ib study evaluating the safety, pharmacokinetics, and preliminary efficacy of LP-118 in subjects with relapsed or refractory haematological malignancies 2022 ·Annals of Oncology ·Emily Curran, John C. Byrd, Wendy Stock, Mary K. Foster, (unknown), (unknown), (unknown), (unknown)	1
13	Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma 2021 ·Blood ·Krish Patel, Jean‐Marie Michot, Asher Chanan‐Khan, Hervé Ghesquières, Kamal Bouabdallah, John C. Byrd, Guillaume Cartron, Craig A. Portell, Melhem Solh, Hervé Tilly, William G. Wierda, (unknown), (unknown), (unknown), Vincent Ribrag, Gabriel Brisou, David Liebowitz, Tycel Phillips	19
14	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients 2021 ·Leukemia ·Cecelia Miller, Ying Huang, Amy S. Ruppert, (unknown), Samantha Jaglowski, Kami J. Maddocks, Kerry A. Rogers, Seema A. Bhat, Adam S. Kittai, Michael R. Grever, Rosa Lapalombella, Lynne V. Abruzzo, Nyla A. Heerema, John C. Byrd, Erin Hertlein, Jennifer A. Woyach	0
15	Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia 2012 ·Leukemia & lymphoma ·Alison R. Walker, Rebecca B. Klisovic, Jeffrey S. Johnston, Yao Jiang, Susan M. Geyer, Cheryl Kefauver, Philip F. Binkley, John C. Byrd, Michael R. Grever, Ramiro Garzon, Mitch A. Phelps, Guido Marcucci, Kristie A. Blum, William Blum	24
16	Assaying pharmacodynamic endpoints with targeted therapy: Flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia 2010 ·PROTEOMICS ·Liwen Wang, Sean W. Harshman, Shujun Liu, Chen Ren, Hua Xu, Larry Sallans, Michael R. Grever, John C. Byrd, Guido Marcucci, Michael A. Freitas	13
17	Rituximab and 17‐allylamino‐17‐demethoxygeldanamycin induce synergistic apoptosis in B‐cell chronic lymphocytic leukaemia 2007 ·British Journal of Haematology ·Amy J. Johnson, Amy J. Wagner, Carolyn Cheney, Lisa L. Smith, David Lucas, (unknown), Michael R. Grever, Thomas S. Lin, John C. Byrd	18
18	FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia 2007 ·Journal of Clinical Investigation ·Paolo Neviani, Ramasamy Santhanam, Joshua J. Oaks, Anna M. Eiring, Mario Notari, Bradley W. Blaser, Shujun Liu, Rossana Trotta, Natarajan Muthusamy, Carlo Gambacorti‐Passerini, Brian Druker, Jörge E. Cortes, Guido Marcucci, Ching-Shih Chen, Nicole M. Verrills, Denis‐Claude Roy, Michael A. Caligiuri, Clara D. Bloomfield, John C. Byrd, Danilo Perrotti	269
19	The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells 2004 ·Leukemia ·David Lucas, Melanie E. Davis, Mark R. Parthun, Andrew P. Mone, Shinichi Kitada, (unknown), (unknown), Joseph Wickham, John C. Reed, John C. Byrd, Michael R. Grever	115
20	Extramedullary Myeloid Cell Tumors in Myelodysplastic-Syndromes: Not a True Indication of Impending Acute Myeloid Leukemia 1996 ·Leukemia & lymphoma ·John C. Byrd, William J. Edenfield, Nancy Dow, Cheryl Aylesworth, Nancy A. Dawson	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact